206
Participants
Start Date
November 15, 2016
Primary Completion Date
July 27, 2018
Study Completion Date
July 27, 2018
Alirocumab SAR236553
"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
Atorvastatin
"Pharmaceutical form: tablet~Route of administration: oral"
Rosuvastatin
"Pharmaceutical form: tablet~Route of administration: oral"
Fenofibrate
"Pharmaceutical form: tablet~Route of administration: oral"
Bezafibrate
"Pharmaceutical form: tablet~Route of administration: oral"
Ezetimibe
"Pharmaceutical form: tablet~Route of administration: oral"
Antiplatelets
"Pharmaceutical form: tablet or capsule~Route of administration: oral"
Anticoagulants
"Pharmaceutical form: tablet or capsule~Route of administration: oral"
Investigational Site Number 392026, Bunkyō City
Investigational Site Number 392022, Chiyoda-ku
Investigational Site Number 392032, Fujisawa-shi
Investigational Site Number 392004, Fukui-shi
Investigational Site Number 392007, Fukuoka
Investigational Site Number 392048, Fukuoka
Investigational Site Number 392008, Gifu
Investigational Site Number 392039, Hiroshima
Investigational Site Number 392028, Isehara-shi
Investigational Site Number 392036, Itabashi-ku
Investigational Site Number 392037, Itabashi-ku
Investigational Site Number 392024, Izumisano
Investigational Site Number 392013, Izunokuni-shi
Investigational Site Number 392020, Kawaguchi-shi
Investigational Site Number 392009, Kitakyushu-shi
Investigational Site Number 392034, Kitakyushu-shi
Investigational Site Number 392044, Kochi
Investigational Site Number 392002, Kumamoto
Investigational Site Number 392011, Kumamoto
Investigational Site Number 392003, Kurashiki-shi
Investigational Site Number 392018, Matsuyama
Investigational Site Number 392021, Morioka
Investigational Site Number 392017, Nagakute-shi
Investigational Site Number 392047, Nagaoka-shi
Investigational Site Number 392033, Okayama
Investigational Site Number 392006, Osaka
Investigational Site Number 392010, Osaka
Investigational Site Number 392045, Osaka
Investigational Site Number 392046, Osaka
Investigational Site Number 392015, Sagamihara-shi
Investigational Site Number 392019, Sakaishi
Investigational Site Number 392035, Sapporo
Investigational Site Number 392001, Tenri-shi
Investigational Site Number 392016, Toyoake-shi
Investigational Site Number 392025, Tsukuba
Investigational Site Number 392040, Tsukuba
Investigational Site Number 392005, Wakayama
Investigational Site Number 392027, Yokohama
Investigational Site Number 392043, Yokohama
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY